These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 18617872

  • 1. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
    Med Lett Drugs Ther; 2008 Jul 14; 50(1290):53-4. PubMed ID: 18617872
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
    Lacy BE, Chey WD.
    Expert Opin Pharmacother; 2009 Jan 14; 10(1):143-52. PubMed ID: 19236188
    [Abstract] [Full Text] [Related]

  • 6. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation.
    Lang L.
    Gastroenterology; 2008 Jul 14; 135(1):7. PubMed ID: 18541153
    [No Abstract] [Full Text] [Related]

  • 7. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.
    Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R.
    Aliment Pharmacol Ther; 2009 Feb 01; 29(3):329-41. PubMed ID: 19006537
    [Abstract] [Full Text] [Related]

  • 8. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.
    Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S, Amercian Gastroenterological Association.
    Gastroenterology; 2014 Nov 01; 147(5):1146-8. PubMed ID: 25224526
    [No Abstract] [Full Text] [Related]

  • 9. Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome?
    Purslow C.
    Expert Rev Gastroenterol Hepatol; 2012 Jun 01; 6(3):263. PubMed ID: 22816171
    [No Abstract] [Full Text] [Related]

  • 10. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
    Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R.
    Aliment Pharmacol Ther; 2012 Mar 01; 35(5):587-99. PubMed ID: 22251419
    [Abstract] [Full Text] [Related]

  • 11. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
    Tack J.
    Expert Rev Gastroenterol Hepatol; 2013 Jul 01; 7(5 Suppl 1):21-6. PubMed ID: 23859757
    [Abstract] [Full Text] [Related]

  • 12. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD.
    Adv Ther; 2009 May 01; 26(5):519-30. PubMed ID: 19444393
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
    Shah E, Kim S, Chong K, Lembo A, Pimentel M.
    Am J Med; 2012 Apr 01; 125(4):381-93. PubMed ID: 22444104
    [Abstract] [Full Text] [Related]

  • 14. Lubiprostone for constipation and irritable bowel syndrome with constipation.
    Tuteja AK, Rao SS.
    Expert Rev Gastroenterol Hepatol; 2008 Dec 01; 2(6):727-33. PubMed ID: 19090733
    [Abstract] [Full Text] [Related]

  • 15. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Saad R, Chey WD.
    Expert Rev Gastroenterol Hepatol; 2008 Aug 01; 2(4):497-508. PubMed ID: 19072397
    [Abstract] [Full Text] [Related]

  • 16. Lubiprostone for chronic constipation in adults.
    Drug Ther Bull; 2014 Apr 01; 52(4):42-4. PubMed ID: 24722574
    [Abstract] [Full Text] [Related]

  • 17. FDA approves one drug for irritable bowel syndrome but suspends another.
    Harv Womens Health Watch; 2008 Aug 01; 15(12):7. PubMed ID: 19115501
    [No Abstract] [Full Text] [Related]

  • 18. Commentary: long-term lubiprostone for constipation predominant IBS.
    Quigley EM.
    Aliment Pharmacol Ther; 2012 Apr 01; 35(8):962-3. PubMed ID: 22436041
    [No Abstract] [Full Text] [Related]

  • 19. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome.
    Chang L, Lembo A, Sultan S.
    Gastroenterology; 2014 Nov 01; 147(5):1149-72.e2. PubMed ID: 25224525
    [No Abstract] [Full Text] [Related]

  • 20. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
    Chamberlain SM, Rao SS.
    Expert Opin Drug Saf; 2012 Sep 01; 11(5):841-50. PubMed ID: 22834474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.